Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (644)	8/10/1999 5:48:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

Real pain: On May 11, 1998, the Company completed a private placement of 2,537,500 shares of common stock to a group of institutional investors at a price of $4.00 per share and received net proceeds of approximately $9,226,000 after deducting selling commissions and offering expenses. ARIA was a $4 1/2 dollar stock back then. The flurry of activity on the thread is a little strange, suggests to me that something is going to happen either way. I cant believe that you all suddenly woke up to Ariad just now--not with me thrashing around on all the biotech threads these past few months. Is there something magic about a buck? Was there anything to my suggestion that the C holders will not want to see a delisting? The sad part is that I'm going to get stopped out of this, and on that day a few of you will finally be starting positions. Saw a few papers in Nature which mention Wingless --threw this post together for fun: messages.yahoo.com I see this thread made it up pretty high on the hot list yesterday. Newbies should know that a casual interest is exactly enough to get yourself into pretty big trouble--I've most certainly screwed myself, and mistakes are made to be punished. I'm not the sharpest tool in the shed

To: Pseudo Biologist who wrote (644)	8/10/1999 6:03:00 PM
From: John Dwyer	Read Replies (1) \| Respond to of 4474

Yeah, I agree. See my "duck" post on the floorless thread. What an ugly mess! Well, I'll still hold for now. I can always sell off in Dec for tax purposes if nothing positive materializes. Great info, folks. Sorry to resurrect this issue again but it was informative. John

To: Pseudo Biologist who wrote (644)	8/11/1999 2:33:00 PM
From: squetch	Read Replies (1) \| Respond to of 4474

BRIAN YEH PROMETHEAN INVESTMENT GROUP, New York) Specialists in the structuring, execution and management of private investments in non-traditional convertible securities of US public corporations. The funds are called Heracles and Themis, and the strategy is based upon structures that are intended to protect investors from downward market movements of the underlying public equities, while preserving opportunities to benefit from volatility and upward appreciation of the underlying equities. Annualised returns of 30% since inception mid 1996; managing approximately $100 million. Both Brian and James were at Fletcher Asset Management prior to founding Promethean. edgeevents.com relevant is 6/8/98-> sec.gov biz.yahoo.com NORWALK, Conn., Aug. 6 /PRNewswire/ -- Purdue Pharma L.P. today announced the execution of a definitive agreement whereby Purdue Acquisition Corporation, an indirect wholly-owned subsidiary of Purdue Pharma L.P., would offer to purchase for cash all outstanding shares of CoCensys, Inc. (OTC Bulletin Board: COCN - news) common stock for $1.16 per share. The board of directors of CoCensys has unanimously approved the transaction and resolved to recommend that CoCensys shareholders accept the offer. Under the terms of the merger agreement, Purdue Acquisition Corporation will promptly commence a tender offer for all of the outstanding common shares of CoCensys, Inc. Simultaneously with the execution of the merger agreement, Purdue Acquisition Corporation entered into a purchase agreement with the holder of the Series E Convertible Preferred Stock of CoCensys, pursuant to which Purdue Acquisition Corporation has agreed to purchase all of the Series E Preferred Stock upon consummation of the tender offer. The Series E Preferred Stock is convertible into approximately 28% of the fully diluted shares of common stock of CoCensys. Purdue Acquisition Corporation plans to convert the Series E Preferred Stock into common stock immediately following consummation of the tender offer. Purdue Acquisition Corporation's tender offer is conditioned upon, among other things, there being validly tendered and not withdrawn such number of shares that, when added to the number of shares of common stock to be received by Purdue Acquisition Corporation upon conversion of the Series E Preferred Stock, equals at least ninety percent of the fully diluted outstanding common shares of CoCensys. After the consummation of the tender offer, Purdue Acquisition Corporation has agreed to acquire any of the remaining outstanding shares of CoCensys pursuant to a second-step merger at the same price per share paid for shares tendered.